Why the study?
Does the cTnI assay on the Dimension RxL-HM analyzer accurately and sensitively detect myocardial damage across various clinical settings?
Does the cTnI assay on the Dimension RxL-HM analyzer accurately and sensitively detect myocardial damage across various clinical settings?
The cTnI assay on the Dimension RxL-HM analyzer is a fast and sensitive method for detecting myocardial damage across various clinical scenarios.
May support sensitive cTnI detection in unstable angina; leaves open validation across broader clinical settings.
The evaluation of cardiac troponin I (cTnI) on the Dimension RxL-HM analyzer is presented. The one-step enzyme immunoassay is based on two cTnI specific monoclonal antibodies. Performed on a separate module of the analyzer, assay-time is 17 minutes. Using as criterion a between-run impression CV <20% the functional limit of detection was set at 0.1 microg/l. Cutoff level for minor myocardial damage of 0.1 microg/l was found. In Duchenne's dystrophy, patients showed increased cardiac Troponin T (cTnT) but no increased cTnI. In patients with a history of coronary heart disease undergoing chronic hemodialysis, cTnT and cTnI were increased. In different patients with submassive pulmonary embolism, increased cTnI was determined. In coronary artery bypass surgery without perioperative myocardial infarction, patients with extracorporeal circulation showed significantly higher cTnI at 24 h after surgery than those with minimal cardiac surgery. In patients with unstable angina, increased cTnI was found more often than on Stratus analyzer. In conclusion, the new assay is a very sensitive cTnI assay, fast and easy to perform in parallel to enzyme and substrate assays.
No takes yet. Share an insight, caveat, or question.
Häfner et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: